Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/msc.1595 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
TNFα-inhibitors cycling with golimumab as second drug in inflammatory arthritis patients: Data from the multicenter GO-REAL registry.
Reumatol Clin (Engl Ed)
December 2024
Rheumatology Section, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina. Electronic address:
Article Synopsis
- This study evaluated the effectiveness and persistence of golimumab (GLM) in patients with rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis who previously used other TNF inhibitors compared to those who haven't.
- A total of 192 patients were included, with follow-up results indicating that the majority discontinued GLM due to inefficacy, and the median survival for GLM treatment was similar for both experienced and naive patients.
- The study concluded that prior TNFi experience did not significantly affect the survival or persistence of GLM treatment, but having public health insurance was linked to higher discontinuation rates.
Incidence and risk factors of discontinuation of tofacitinib and biologic disease-modifying anti-rheumatic drugs among patients with rheumatoid arthritis: A population-based cohort study.
Clin Rheumatol
December 2024
Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Xitun District, No. 1650, Sec. 4, Taiwan Blvd., Taichung, 40705, Taiwan.
Article Synopsis
- This study analyzed the discontinuation rates of tofacitinib and various biologic DMARDs in 5,008 rheumatoid arthritis patients between 2014 and 2020.
- Tofacitinib had the lowest discontinuation rate (21.8%) compared to etanercept (43.27%) and showed lower risks than other bDMARDs.
- Key factors influencing drug discontinuation included higher steroid dosages and existing connective tissue diseases increasing risk, while methotrexate use decreased the likelihood of discontinuation.
Factors associated with cause-specific discontinuation of long-term anti-tumor necrosis factor agent use in patients with ankylosing spondylitis: a retrospective cohort study.
BMC Rheumatol
August 2024
Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, 222-1 Wangsimni- ro, Seongdong-gu, Seoul, 04763, Republic of Korea.
Article Synopsis
- - The study examined the reasons behind the lasting use or discontinuation of anti-TNF medications in patients with ankylosing spondylitis (AS) from 2004 to 2018, focusing on multiple factors like clinical remission and adverse effects.
- - Out of 429 AS patients, 24% discontinued treatment, primarily due to loss of efficacy (34.9%) and clinical remission (30.1%), with those using etanercept (ETN) experiencing fewer discontinuations for clinical remission than those on adalimumab (ADA).
- - Key findings indicated that higher disease activity at baseline increased the risk of discontinuation due to inefficacy, while older age was also associated with a greater likelihood of
Early identification of golimumab-treated patients with higher likelihood of long-term retention.
Front Immunol
April 2024
Departamento de Reumatología, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain.
Background: The early identification of patients' profiles most likely to respond to and maintain long-term therapy with a biological drug can have clinical and cost-effectiveness implications.
Objectives: To evaluate the utility of an innovative approach for early identification of patient profiles associated with long-term persistence of golimumab, a tumour necrosis factor inhibitor, in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (SpA) under real-world conditions.
Design: Retrospective non-interventional database analysis.
Retention rate of subcutaneous TNF inhibitors in axial spondyloarthritis in a multicentre study from the RIC-FRANCE network.
Sci Rep
January 2024
LITEC, Université de Poitiers, CHU Poitiers, 86000, Poitiers, France.
Article Synopsis
- The study evaluated the retention rates, safety, and predictive factors for the use of subcutaneous TNF inhibitors (TNFi) in patients with axial spondyloarthritis (axSpA) based on real-life data from 552 patients.
- Results indicated that golimumab (GOL) had a significantly higher retention rate compared to adalimumab (ADA), etanercept (ETN), and certolizumab pegol (CZP), especially when prescribed as the first treatment option.
- Predictive factors for treatment cessation included female sex, peripheral disease, and the line of treatment, with primary inefficiency being the most common reason for stopping treatment.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!